- Home
- RNAZ vs NCNA Comparison
RNAZ vs NCNA Comparison
Compare RNAZ & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNAZ | NCNA |
|---|---|---|
| Founded | 2016 | 1997 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 5.5M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RNAZ | NCNA |
|---|---|---|
| Price | $1.65 | $1.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 50.8K | ★ 61.2K |
| Earning Date | 04-15-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.63 | $1.21 |
| 52 Week High | $20.99 | $7.01 |
Technical Indicators
Market Signals| Indicator | RNAZ | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 23.92 | 41.98 |
| Support Level | N/A | $1.33 |
| Resistance Level | $9.37 | $1.41 |
| Average True Range (ATR) | 0.22 | 0.09 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 1.89 | 3.45 |
Price Performance
Historical ComparisonAbout RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.